Intermediate Fellowships in Public Health and Tropical Medicine: people we've funded

This list includes current and past grantholders.


Mohlopheni Marakalala

University of Cape Town, South Africa

Human tuberculosis granulomas as targets for host-directed therapies and prediction of disease progression

Tuberculosis (TB) is a bacterial disease that is responsible for 1.5 million deaths every year. The problem is worsened by increasing numbers of patients responding poorly to current standard treatment. There is an urgent need for new treatment and diagnostic tools. TB disease progression is characterised by a combination of bacterial growth and immune-mediated lung damage. Typically, lung damage is characterised by dissociation of granulomas, which are complex cellular structures that restrict bacteria. However, granulomas can develop caseum, a key feature of lung damage. Inhibition of factors associated with granuloma caseation presents an attractive area for discovery of drugs that can limit tissue destruction.

In our recent work, we demonstrated that proteomics can be used to determine events that shape a TB granuloma. We also found that important factors required for TB granuloma development are regionally distributed, with pro-inflammatory proteins enriched in the caseum. We will investigate proteins that are associated with caseum formation and tissue damage and develop host-directed therapies to decrease the damage. We will also characterise macrophage functional diversity in granulomas and develop predictive biomarkers that can be used to diagnose those at highest risk for caseation.

Our findings will help improve TB treatments.

Patrick Munywoki

KEMRI-Wellcome Trust Research Programme, Kenya

Quantifying the burden and economic costs of life-threatening disease, mortality and long-term sequelae associated with respiratory syncytial virus in low and middle-income settings

Respiratory syncytial virus (RSV) is the most important cause of severe acute respiratory disease in young children worldwide. Several promising vaccines are in advanced stages of clinical testing, raising the interests of international agencies, such as WHO, in accelerating the pathway to implementation.

I will provide much-needed data on severe RSV disease in young and older age groups, the associated risk of death, the predisposition to long-term respiratory problems that follows RSV disease in infancy and the associated costs of seeking treatment. The data will be acquired through KEMRI-Wellcome Trust research programme sites in Kenya and Uganda and will be used to quantify the full burden of RSV-linked diseases and support cost-effectiveness analyses of vaccines in settings with low resources. I will use our previously developed mathematical models to evaluate the impact and value for money of several vaccination strategies to protect infants and young children from RSV disease in Kenya and other similar settings.

The findings have the potential to inform potential funding budgets as well as helping to establish a fair and cost-effective price for an RSV vaccine in developing countries.

Nguyen Thuong

University of Oxford Clinical Research Unit, Vietnam

Linking human genotype and immunological phenotype to understand pathogenesis and improve treatment in tuberculosis

Tuberculosis (TB) kills more people worldwide than any other infectious disease, but if we are to reduce this burden we need to better understand how the disease develops. TB is a complicated disease with many different clinical forms and variations in human genes which affect how the body responds to infection and how a person responds to treatment.

My aim is to better understand the links between human genes and the type and severity of disease. I will investigate TB affecting the lung and brain in adults in Vietnam by analysing the genetic messaging (RNA) expressed by the body to make proteins. This will allow me to compare the body’s response in different forms of TB, particularly inflammation, and assess how different treatments are working. I will investigate: the impact of the anti-inflammatory drug dexamethasone on TB-associated inflammation; the body’s ability to kill bacteria and survival or death from TB in the brain; and how the gene LTA4H affects inflammation. I will also identify other genes that alter inflammation and outcome from TB in the brain and investigate how genes and inflammation are associated with treatment failure or relapse in TB in the lung.

My results will help improve understanding of the links between human genes and the type and severity of TB and this will help improve treatments.


Dr Kebebe Deribe

Addis Ababa University, Ethiopia

Global atlas of Podoconiosis

Podoconiosis is a disfiguring swelling of the leg that imposes social and economic burdens on affected individuals. It can affect productivity and significantly compromise the development of endemic communities. Podoconiosis was included in the World Health Organization’s (WHO) list of neglected tropical diseases in 2011, but despite this the global distribution, burden and list of endemic countries is unknown. Partly this is due to a lack of understanding of the disease burden and its geographical distribution. Mapping the geographical distribution of the disease is the first step in launching control interventions. Mapping will provide information about where the disease occurs, identify priority areas which need interventions and quantify the population that is potentially exposed to the disease. Such information is useful in designing, monitoring and evaluating interventions using the data generated as a benchmark.

I intend to map the disease’s distribution in a global atlas of podoconiosis, estimating the number of people affected, the working years lost to podoconiosis-associated disability and the economic cost of the disease.

This research will generate information essential to the planning of control and elimination of podoconiosis in countries where the disease is common.

Diane Gray

University of Cape Town, South Africa

The impact of early life exposures on chronic respiratory illness in African children

Lung disease is a leading cause of death in children and chronic lung disease (CLD), such as asthma and chronic obstructive lung disease (COPD), is a major contributor to global disease burden. Lung disease and low lung function in infancy may increase a person’s risk for CLD in later life. Protecting the lungs from early damage may reduce the risk of CLD, important in low and middle-income countries (LMIC) where the burden is so high.

We have followed 1,000 infants enrolled in an African cohort from birth to three years. Our research identified antenatal and early life exposures that impair normal lung function and we have shown that pneumonia in early life leads to altered infant lung function. We are now following these children up to age six, collecting comprehensive information about risk factors and measuring their lung function every year. This will help us better understand the impact of early exposures such as pneumonia on lung health at six years. 

This research will help us understand why children get lung disease and identify the most important risk factors for progression of lung disease. This information may help us identify targets for reducing CLD and strengthening lung health, particularly in LMIC.

Tan Le Van

University of Oxford Clinical Research Unit, Vietnam

The translational potential of mass spectrometry and next-generation sequencing in patients with central nervous system infections in Vietnam

Brain infections are common in low- and middle-income countries and are often fatal. Doctors are currently hamstrung by the inadequacy of laboratory tests, especially in poorer parts of the world. They often do not know what caused the infection and are unable to give effective treatment. The situation is exacerbated by the emergence of new, previously unrecognised infections and infections that are resistant to antibiotics.

I aim to show that new diagnostic tests targeted at proteins found in the brain fluid of patients and the genetic material of infectious agents can improve upon tests commonly used in hospitals in Vietnam. I will recruit 750 patients with brain infections over three years at the Hospital for Tropical Diseases in Ho Chi Minh City, Vietnam. I will analyse brain fluid from these patients to discover whether the proteins in the fluid can tell us what is causing the infection and determine if finding the complete genetic code of the bug causing the infection is better than current conventional tests. I will also determine if the genetic code can rapidly predict antibiotic resistance and guide effective treatment.

Improving tests so that doctors can quickly determine the cause of the central nervous system infections and decide which antibiotics will be effective will help patients with brain infections worldwide.

Dr Emelda Okiro

KEMRI-Wellcome Trust Research Programme, Kenya

Identifying sub-national disparities and determinants of under-five mortality in Kenya 1990-2020

The number of child deaths occurring between birth and age five has been declining. However, the slowest rates of decline have been in sub-Saharan Africa, with important differences between and within countries. It is important to understand regional differences in mortality risk and the levels of intervention coverage to facilitate better planning and resource allocation. In many African countries the estimates for child mortality are obtained from national household surveys that manage to generate estimates only for populations too large to really inform effective local planning or measure local progress. Information from smaller geographical units is essential and there are scientific methods that have been developed to do this using existing data.

This project aims to produce estimates of child mortality and determine the prevalence of risk factors at the county level (the new unit of health planning used by the Ministry of Health) at different time points. Models will be developed to analyse the dynamics of interventions and risk factors, and their influences on reductions in child mortality at county-level using data from census and surveys.

The results of the study will be used to facilitate improved targeted disease control and effective resource allocation.


Dr Luc Djogbenou

Institute Regional de Sante Publique, Benin

The impact of insecticide resistance and exposure on Plasmodium infection level and prevalence in the malaria vector Anopheles gambiae

Luc is a medical entomologist with an interest in mosquito-parasite interaction, genomics, insecticide resistance, and vector control strategy. He will investigate the role of insecticide resistance mechanisms and direct responses to insecticide exposure in Anopheles gambiae vectorial capacity. He will characterise parasite infection differences in insecticide-resistant mosquito strains displaying the most important resistance mechanisms currently circulating in West Africa. Specifically, the results will reveal which insecticides and resistance mechanisms have the most potential to exacerbate malaria disease outcomes in this region. Luc will also identify the determinants of vectorial capacity that are affected by insecticide resistance alleles and exposure to insecticides commonly used in public health.

Dr Maria Adelaida Gomez

Centro Internacional de Entrenamiento e Investigaciones Medicas (CIDEIM), Colombia

The inflammatory response as a targetable pharmacodynamic parameter of antileishmanial drugs

Maria Adelaida is a microbiologist and the coordinator of the Molecular Biology and Biochemistry Unit at CIDEIM. During her Fellowship she will investigate how immunological factors and antimicrobial drug concentrations interact to drive the therapeutic outcome in patients with cutaneous leishmaniasis. She will explore how inflammation can be exploited as a targetable pharmacodynamic parameter of anti-leishmanial drugs. Her project aims to provide the knowledge base for the design of novel therapeutic schemes that concomitantly optimise antimicrobial and immunological functions for improved efficacy of treatment, and to reduce exposure of patients to toxic systemic drugs.

Dr Isabella Oyier

KEMRI-Wellcome Trust Research Programme, Kenya

A novel strategy for understanding the functional impact of variation in Plasmodium falciparum merozoite vaccine candidates

Isabella is a molecular biologist with an interest in the malaria parasite’s invasion of red blood cells. She works at the KEMRI-Wellcome Trust Research Programme and is a visiting lecturer at the Centre for Biotechnology and Bioinformatics, University of Nairobi. Her Fellowship focuses on understanding the impact of genetic variation in the proteins involved in enabling the malaria parasite (Plasmodium falciparum) via its blood stage (the merozoite) to invade red blood cells. The research uses a combination of molecular epidemiology, immunoepidemiology, cell biology and experimental genetic tools. The project will be carried out in collaboration with Dr Julian Rayner at the Wellcome Trust Sanger Institute.

Dr Francisco Villafuerte

Universidad Peruana Cayetano Heredia, Peru

Mechanisms, cardiometabolic consequences and treatment strategies for high-altitude excessive ertythrocytosis and chronic mountain sickness in the Andes

Francisco is a physiologist with a particular interest in chronic mountain sickness (CMS), a highly-prevalent syndrome in Andean and other high-altitude populations. His research is focused on the pathophysiological mechanisms of excessive erythrocytosis (EE), the hallmark of CMS. Evidence indicates that in addition to frequent complications due to blood hyperviscosity, EE might be also associated with cardiometabolic disorders leading to an important increase in cardiovascular risk. Francisco aims to investigate the mechanisms and cardiometabolic consequences of EE, and explore novel treatment strategies in order to provide information on adequate healthcare and therapeutic approaches for CMS patients.


Dr Kondwani Charles Jambo

Malawi-Liverpool-Wellcome Trust Clinical Research Programme

Investigating the mechanisms for persistence of HIV in human alveolar macrophages

Kondwani is a pulmonary immunologist with a particular interest in immune defence against pathogens in the lung. During his Fellowship, he aims to understand what promotes persistence of HIV in the lung after initiation of antiretroviral therapy. Persistence of HIV in the lung, especially in alveolar macrophages, presents an enormous challenge for the eradication of HIV in the human host. Kondwani’s research will mainly focus on investigating whether HIV suppresses host-immune functions that are key for recognition and clearance of HIV-infected cells in the lung. Understanding the mechanisms that promote persistence of HIV in the lung will help in the formulation of novel therapeutic strategies against HIV.

Dr Christopher Kasanga

Sokoine University of Agriculture, Tanzania

Full-genome sequencing to identify determinants that impact upon foot and mouth disease virus strains with potential for enhanced transmission in endemic settings in Africa

Christopher is a molecular virologist in the Department of Microbiology and Parasitology, Sokoine University of Agriculture. He is interested in the genetic and antigenic novelty of foot and mouth disease virus (FMDV) in endemic settings in Africa. During his Fellowship, he aims to investigate the evolutionary characteristics of FMDV field strains. The main focus is to understand the molecular basis and factors associated with overt antigenicity and future epidemics or spread of foot and mouth disease. Identification of early genomic changes that are likely to lead to broader antigenicity and virulence of FMDV will provide necessary information for defining early interventions including diagnostics, vaccine strain selection and development of novel vaccines.

Dr Charles Masembe

Makerere University, Uganda

Transmission dynamics of African swine fever in an endemic setting at the livestock-wildlife interface

Charles is a veterinarian and molecular epidemiologist. Together with scientists at the MRC-University of Glasgow Centre for Virus Research, he will investigate the role of soft ticks in the spread and maintenance of African swine fever (ASF) in the domestic cycle and wild cycle. He will determine the molecular genetic and evolutionary characteristics of ASF virus in domestic pigs, warthogs, bushpigs and ticks at the livestock-wildlife interface to reveal transmission networks. The results will directly contribute to the development of effective control strategies for this devastating disease that is impeding the development of the pig industry in Uganda and possibly beyond.

Dr Chouaïbou Mouhamadou

Centre Suisse de Recherches Scientifiques, Ivory Coast

Assessment of the role of non-insecticide agrochemicals in selecting resistance to insecticides in the principal malaria vector Anopheles gambiae

Chouaïbou is a medical entomologist with research interests in insecticide resistance and vector control. Selection for insecticide resistance in malaria vectors has often been attributed to exposure to chemicals used in production of cash crops but the evidence is largely associative. Chouaïbou will investigate the role of both insecticide and non-insecticide chemicals found in agricultural wetlands in selecting resistance in mosquitoes breeding in these sites. Chouaïbou’s experiments will enable him to determine whether larval survival of environmental toxicants determines the ability of adult mosquitoes to survive insecticide exposure and whether this response is short-lived, potentially a result of the induction of detoxification enzymes, or whether the larval breeding site is an important source of genetic selection for insecticide resistance.


Dr Jane Chuma

KEMRI-Wellcome Trust Research Programme, Kenya

Moving towards universal health coverage in Kenya: identifying mechanisms to promote sustainable and affordable health system reforms

Dr Direk Limmathurotsakul

Mahidol University, Thailand

Reducing the global burden of melioidosis

Direk is the head of the microbiology department at the Mahidol-Oxford Research Unit, Bangkok. He recently developed the first guidelines for the prevention of melioidosis, an infectious disease caused by an environmental bacterium called Burkholderia pseudomallei. During this Fellowship, he aims to undertake a clinical trial to evaluate whether these guidelines can reduce the incidence of melioidosis in north-east Thailand, and whether they are sufficiently cost-effective if implemented as national health policy. Direk will also identify countries where melioidosis might be present but under-recognised, and he will predict whether implementation of the preventive guidelines will be cost-effective in those areas.

Dr Jean Louis Ndiaye

University Cheikh Anta Diop, Senegal

Evaluation of the impact of seasonal malaria chemoprevention delivered by district health services in southern Senegal

Jean Louis is a malariologist working in the Department of Medical Parasitology at the University Cheikh Anta Diop, Dakar. This department, headed by Professor Oumar Gaye, is a reference research centre with a leading role in both fundamental and operational research in Senegal. Jean Louis’s Fellowship is focused on measuring the impact of seasonal malaria chemoprevention on the incidence of malaria and on child deaths. He will monitor the effects of this new strategy for malaria control on the sensitivity of Plasmodium falciparum and on natural acquisition of immunity to malaria, in collaboration with Dr Paul Milligan, an epidemiologist from the London School of Hygiene and Tropical Medicine.

Dr Wang Nguitragool

Mahidol University, Thailand

Elucidating the mechanism of reticulocyte-specific invasion by Plasmodium vivax

Wang is a biochemist with an interest in malaria. He is based at the Faculty of Tropical Medicine, Mahidol University, Thailand. During this Fellowship, he is working on erythrocyte invasion by Plasmodium vivax. Using archived blood samples, fresh parasites from malaria patients and short-term in vitro culture, he aims to elucidate the mechanism of reticulocyte specificity and examine the repertoire of invasion pathways of this important but often neglected parasite.  

Dr Fredros Okumu

Ifakara Health Institute, Tanzania

Targeting residual malaria vectors in communities where insecticidal bednets are already widely used

Fredros is a public health specialist who focuses on biology and control of disease vectors. The goal of his project is to develop an easy-to-implement strategy for locating and targeting residual mosquito populations that perpetuate malaria transmission in communities where most people already use insecticidal bednets. There is an overwhelming lack of effective surveillance strategies for mosquitoes that mediate persistent malaria transmission in communities where indoor interventions like insecticidal bednets are already widely used. This greatly hinders efforts to measure progress or target interventions against these residual vectors, a substantial proportion of which also readily bite humans outdoors and can survive on non-human host blood. Fredros’s project is therefore expected to improve targeting of future malaria elimination efforts.

Dr Patricia Sheen

Universidad Peruana Cayetano Heredia, Peru

Unravelling the resistance mechanism of pyrazinamide, the unique sterilising drug against tuberculosis

Patricia will study the molecular aspects of the mechanism of action and resistance to pyrazinamide in Mycobacterium tuberculosis (MTB). Pyrazinamide is one of the most important drugs in tuberculosis treatment. Patricia will study the effect of mutations in metallochaperones and will search the gene encoding the pyrazinoic acid efflux pump that participates in the action mechanism. Finally, she will develop a sensitive and fast assay for detection of pyrazinamide resistance based in the quantitation of extracellular pyrazinoic acid. This study will significantly contribute to the basic understanding of pyrazinamide resistance in MTB and to efforts to control tuberculosis.


Dr Helen Cox

University of Cape Town, South Africa

A systems approach to evaluating prospects for the control of drug-resistant tuberculosis in Khayelitsha, South Africa

Helen is an epidemiologist with a particular interest in drug-resistant tuberculosis. Her Fellowship work aims to determine what is needed to effectively treat patients and reduce the incidence of drug-resistant tuberculosis in a South African township where there is a high burden of both HIV and TB. She aims to do this by matching clinical data with information on the exact TB bacteria that are infecting each patient, and assessing changes over time. Specifically, the research aims to determine whether currently available diagnostic tools and treatment regimens will be sufficient to control the drug-resistant TB epidemic, and if not, what improvements will provide the greatest benefit.

Dr James Futse

University of Ghana

Anaplasmosis vaccine development for West Africa: genetic and immunologic analysis of endemic strains

James’s research goal is to identify pathways towards multi-pathogen-based vaccine development and deployment in West Africa. He is based at the College of Agriculture and Consumer Science, University of Ghana. James has initiated research addressing the diversity of the outer membrane proteins of Anaplasma marginale, the most prevalent tick-borne pathogen of cattle. The antigenic conservation of these antigens with those of strains in Africa is unknown, but clearly required to progress on vaccine development. During his Fellowship, James has implemented diagnostic assays for tick-borne infectious diseases of livestock in his laboratory. Using these, he has identified endemic zones, isolated pathogens, intiated sequencing of potential vaccine candidates and established working relationships with farmers in these areas.

Dr Julie Makani

Muhimbili University of Health and Allied Sciences, Tanzania

The role of anaemia and fetal haemoglobin in sickle-cell disease: clinical epidemiology to establish the evidence base for interventional trials of blood transfusion and hydroxyurea

Julie’s work is focused on sickle-cell disease (SCD) and is based at Muhimbili University of Health and Allied Sciences in a programme integrating healthcare, research and training. Her Fellowship is held at Muhimbili and the Nuffield Department of Clinical Medicine, University of Oxford. Julie is looking at anaemia in SCD, determining the epidemiology of disease, and establishing interventions including blood transfusion and hydroxyurea. She is exploring disease mechanisms and disease-modifying factors - both genetic and environmental - that influence SCD, with collaborations in Africa, USA and the UK (London School of Hygiene and Tropical Medicine, King’s College London and Wellcome Trust Sanger Institute).

Professor Graeme Meintjes

University of Cape Town, South Africa

Defining interventions to reduce mortality in severe HIV-associated tuberculosis

Graeme is using his Fellowship to investigate pathogenic mechanisms and co-infections contributing to the high case fatality rate observed among hospitalised patients with HIV-associated tuberculosis (HIV-TB) in sub-Saharan Africa. A large prospective observational study (n=660) at Khayelithsa District Hospital in Cape Town will address what contribution sepsis syndrome, translocation of gastrointestinal bacteria and bacterial products, cytomegalovirus, compensatory anti-inflammatory signalling, and suboptimal exposure to anti-tubercular drugs make to mortality in HIV-TB. The broad aim of this study is to define interventions to reduce mortality in HIV-TB that will be tested in clinical trials.

Dr Standwell Nkhoma

University of Malawi

Intrahost dynamics in treated and untreated malaria patients

Standwell is a molecular biologist based at the Malawi-Liverpool-Wellcome Trust Clinical Research Programme. His Fellowship project aims to study the biology of multiple-genotype malaria infections from an area of high disease burden in Malawi. Multiple-genotype infections are extremely common in Africa, and present enormous challenges for both malaria research and control. Standwell will undertake a detailed characterisation of these complex infections using novel single-cell genomics approaches to better understand their genetic composition and to evaluate the relationship between within-host parasite diversity and malaria disease severity.

Dr Dorothy Yeboah-Manu

University of Ghana

Understanding the genetic diversity between Mycobacterium africanum and Mycobacterium tuberculosis

Dorothy is a microbiologist based in the bacteriology department of the Noguchi Memorial Institute for Medical Research. She is interested in host-pathogen interactions in mycobacterial infections. During her Fellowship, she aims to determine the transmission dynamics of TB and analyse for genomic diversity and differing gene expression profiles between Mycobacterium tuberculosis and Mycobacterium africanum (prevalent only in West Africa). Understanding the diversity between the two main pathogens that cause TB in humans will provide useful information for new antigens, for both diagnostics and vaccine development, as well as targets for new drug design.


Dr Abdisalan Mohamed Noor

KEMRI-Welcome Trust Research Programme, Kenya

Mapping the risks of Plasmodium falciparum infections in areas of low transmission intensity

Abdisalan is based at the KEMRI-Wellcome Trust Research Programme. His broad areas of research include access to healthcare, mapping of malaria transmission, populations at risk, and the coverage and impact of malaria control interventions in Africa, specifically Namibia, Somalia, Sudan and Djibouti. His Fellowship focuses on developing methods for mapping the risks of Plasmodium falciparum infections in areas of low transmission intensity in Africa.


Dr Penny Moore

National Health Laboratory Service, South Africa

Autologous neutralising antibody specificities in HIV-1 subtype C: characterising the targets and defining the mechanisms of escape

Penny’s research aims to understand the dynamic interplay between virus and host in people infected with HIV-1. Her focus is particularly on rare individuals who naturally develop broadly neutralising antibodies. These are the types of antibodies an HIV vaccine will need to elicit, and so understanding how they develop may enable the design of novel HIV immunogens. Penny works at the National Health Laboratory Service, Johannesburg, with Professor Lynn Morris and collaborates with Professor Carolyn Williamson at the University of Cape Town.


Dr Christophe Antonio-Nkondjio

OCEAC, Cameroon

Impact of urbanisation on malaria vector population dynamic in two major cities of Cameroon

Christophe is a medical entomologist with research interests in malaria vector biology and vector control. He is based at the Malaria Research Laboratory of OCEAC Yaoundé. His goals include: mapping the distribution of urban breeding sites of malaria vectors to guide potential larviciding activities; assessing the molecular basis of insecticide resistance mechanisms and patterns of cross-resistance with xenobiotics found in breeding sites; and assessing the influence of insecticide resistance on mosquito capacity to transmit malaria. Understanding all of these factors could improve vector control strategies in Cameroon.

Dr Wendy Burgers

University of Cape Town, South Africa

Immune activation in HIV infection: investigating mediators and mechanisms

Wendy is an immunologist who has an interest in immunity to the major infectious pathogens, HIV and TB. Her Fellowship supports her research into understanding the mechanisms of how HIV drives excessive activation of the immune system. Wendy’s research group is based at the Institute of Infectious Disease and Molecular Medicine at the University of Cape Town.

Dr Narisara Chantratita

Mahidol University, Thailand

Associations between genetic polymorphisms, innate immune responses, and outcomes from sepsis in Thai patients with melioidosis and S. aureus infection

Narisara is based at the Faculty of Tropical Medicine, Mahidol University. Her Fellowship has supported her research on pathogenesis, diagnosis, immune response and host genetic polymorphisms associated with bacterial infections. The project is mainly focused on the hypothesis that polymorphisms affecting Toll-like receptor-mediated responses predispose to excessive inflammation during melioidosis and S. aureus sepsis, and contribute to poor outcomes from these infections.

Dr Faith Osier

Kenya Medical Research Institute

Comprehensive analysis of the antibody targets of Plasmodium falciparum merozites and identification of antigens important in the development of naturally acquired immunity to malaria

Faith is a clinician scientist and is conducting research focused on understanding how humans acquire immunity to malaria. Her main aim is to translate this knowledge into effective malaria vaccines. Faith’s Fellowship has supported her in studying the merozoite stages of Plasmodium falciparum, to comprehensively identify the targets of naturally acquired protective immunity against malaria. She is based at the Kenya Medical Research Institute, Kilifi, Kenya, where she works with Professor Kevin Marsh. Her main collaborator on this project is Professor James Beeson at the Burnet Institute, Melbourne, Australia.

Other grant holders